Shares of Pfizer Inc. (NYSE: PFE) were up on Tuesday despite the company delivering mixed results for the fourth quarter of 2022
Pfizer Inc.
-(PFE)
XNYS:PFE
PFE Earnings: Key quarterly highlights from Pfizer’s Q4 2022 financial results
Pfizer Inc. (NYSE: PFE) reported fourth quarter 2022 earnings results today. Revenues increased 2% year-over-year to $24.3 billion but missed estimates. Reported
Four noteworthy points from Pfizer’s (PFE) Q3 2022 earnings report
Shares of Pfizer Inc. (NYSE: PFE) were up 3% on Tuesday after the company beat estimates for the third quarter of 2022
Pfizer (PFE) Q3 2022 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported third quarter 2022 earnings results today. Revenues decreased 6% year-over-year to $22.6 billion. Reported net income increased
Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term
Shares of Pfizer Inc. (NYSE: PFE) were down on Monday. The stock has dropped 15% year-to-date and there is a mixed sentiment
Pfizer Inc. (PFE) Q2 2022 Earnings Call Transcript
Pfizer Inc. (NYSE: PFE) Q2 2022 earnings call dated Jul. 28, 2022 Corporate Participants: Christopher Stevo -- Senior Vice President and Chief Investor Relations
Pfizer (PFE) Q2 2022 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported second quarter 2022 earnings results today. Total revenues increased 47% year-over-year to $27.7 billion. Reported net income
Is Merck & Co. (MRK) a good investment after Q1 earnings?
Merck & Co., Inc. (NYSE: MRK) is recovering from the virus-induced slowdown supported by stable demand across its product line globally, a
Infographic: Highlights of Merck’s (MRK) Q1 2022 earnings
Pharmaceuticals company Merck & Co., Inc. (NYSE: MRK) has reported stronger-than-expected earnings and revenues for the first quarter of 2022. The positive outcome
Pfizer Inc. (PFE) Q1 2022 Earnings Call Transcript
Pfizer Inc. (NYSE: PFE) Q1 2022 earnings call dated May. 03, 2022 Corporate Participants: Chris Stevo -- Senior Vice President and Chief of Investor
Stock Watch: Should you invest in Eli Lilly (LLY) after Q1 earnings?
For Eli Lilly and Company (NYSE: LLY), 2021 was a fruitful year in terms of financial performance and product development. Reflecting the
Pfizer (PFE) anticipates an increase in orders for Paxlovid in coming months due to virus mutations
Shares of Pfizer Inc. (NYSE: PFE) gained nearly 2% on Tuesday after the company delivered better-than-expected results for the first quarter of
PFE Earnings: All you need to know about Pfizer’s Q1 2022 earnings results
Pfizer Inc. (NYSE: PFE) reported first quarter 2022 earnings results today. Total revenues increased 77% year-over-year to $25.7 billion. Reported net income
Earnings: Highlights of Eli Lilly’s (LLY) Q1 2022 results
Eli Lilly and Company (NYSE: LLY) has reported higher earnings and revenues for the first quarter of 2022. The numbers also surpassed
Why Intuitive Surgical (ISRG) is a must-own stock after the recent dip
The pandemic had a mixed impact on the healthcare sector. The high demand for COIVD care services sent medical facilities into overdrive,
AN2 Therapeutics takes IPO route to advance pipeline. Here’s all you need to know
After starting the year on a high note, the IPO market is currently going through a slow phase mainly due to the
Pfizer Inc. (PFE) Q4 2021 Earnings Call Transcript
Pfizer Inc. (NYSE: PFE) Q4 2021 earnings call dated Feb. 08, 2022 Corporate Participants: Chris Stevo -- Senior Vice President and Chief Investor Relations
PFE Earnings: All you need to know about Pfizer’s Q4 2021 earnings results
Pfizer Inc. (NYSE: PFE) reported fourth quarter 2021 earnings results today. Revenues doubled year-over-year to $23.8 billion. Excluding contributions from Comirnaty and
Infographic: A snapshot of Merck’s Q4 2021 earnings
Pharmaceuticals company Merck & Co., Inc. (NYSE: MRK) has reported stronger-than expected earnings and revenues for the fourth quarter. The positive outcome
Bristol-Myers bets on product pipeline to beat patent issues. Is BMY a buy?
The pharma sector has been on a stable growth trajectory lately, and the trend gathered momentum when the pandemic-related emergency made companies
Biofrontera sees TAM of $4 Bln for lead product Ameluz: CEO Erica Monaco
Caption: iStock Biofrontera Inc. (Nasdaq: BFRI) is a biopharmaceutical company providing specialty dermatology therapies and services in the United States. Founded in